Iterum Therapeutics plc (ITRM) Bundle
A Brief History of Iterum Therapeutics plc (ITRM)
Company Formation and Focus
Company Formation and Focus
Iterum Therapeutics plc was founded in 2016 with a mission to develop innovative anti-infectives. The company is primarily focused on addressing the global health crisis of antibiotic-resistant infections, particularly in the area of urologic infections.
Initial Public Offering
On July 25, 2019, Iterum Therapeutics went public on the NASDAQ under the ticker symbol ITRM. The company raised approximately $60 million through its initial public offering, with an IPO price of $12.00 per share.
Key Drug Development
Iterum’s lead product candidate, sulopenem, is the first oral formulation of a carbapenem antibiotic. It is designed to treat complicated urinary tract infections (cUTI) and acute pyelonephritis. The company initiated a Phase 3 clinical trial for sulopenem in 2019, known as the APPRISE trial.
Financial Performance
| Year | Revenue (in millions) | Net Loss (in millions) | Cash and Cash Equivalents (in millions) |
|---|---|---|---|
| 2019 | 0 | (32.6) | 54.7 |
| 2020 | 0 | (30.3) | 29.3 |
| 2021 | 0 | (26.5) | 15.1 |
| 2022 | 0 | (18.4) | 8.7 |
| 2023 (Q1) | 0 | (7.2) | 5.5 |
Recent Developments
In March 2023, Iterum Therapeutics announced the completion of its Phase 3 trials for sulopenem, with results indicating a statistically significant improvement in patients with cUTI. The company is currently preparing for regulatory submissions to the FDA.
Challenges and Strategic Changes
Despite positive advancements in drug development, Iterum faced significant operational challenges, including funding and market competition. As a result, Iterum Therapeutics announced a strategic review in 2022 aimed at optimizing its capital resources and exploring potential collaborations.
Current Status
As of September 2023, Iterum Therapeutics reported a total of $5.5 million in cash and cash equivalents. The company continues to focus on advancing sulopenem through the regulatory process while seeking potential partnerships to enhance its financial stability.
A Who Owns Iterum Therapeutics plc (ITRM)
Shareholder Structure
As of the latest financial data in 2023, Iterum Therapeutics plc has the following shareholder structure:
| Shareholder | Ownership Percentage | Shares Owned |
|---|---|---|
| Institutional Investors | 45% | 10,000,000 |
| Retail Investors | 25% | 5,500,000 |
| Company Executives and Directors | 15% | 3,500,000 |
| Other Stakeholders | 15% | 3,500,000 |
Major Institutional Holders
The largest institutional holders of Iterum Therapeutics plc as of Q1 2023 are:
| Institution | Shares Held | Ownership Percentage |
|---|---|---|
| BlackRock, Inc. | 2,000,000 | 9% |
| Vanguard Group, Inc. | 1,500,000 | 6.5% |
| State Street Corporation | 1,000,000 | 4.5% |
| Invesco Ltd. | 800,000 | 3.5% |
Board of Directors Ownership
The board of directors holds a significant portion of the company. The details are as follows:
| Name | Position | Shares Owned |
|---|---|---|
| Dr. Michael W. Wyzga | CEO | 1,000,000 |
| Dr. John D. McKinley | Chairman | 500,000 |
| Ms. Susan L. Roberts | CFO | 300,000 |
Recent Financial Performance
For fiscal year 2022, Iterum Therapeutics plc reported:
- Revenue: $4 million
- Net Loss: $12 million
- Total Assets: $25 million
- Total Liabilities: $15 million
Stock Performance
As of October 2023, the stock performance metrics are as follows:
| Metric | Value |
|---|---|
| Current Stock Price | $0.40 |
| Market Capitalization | $50 million |
| 52-Week High | $1.20 |
| 52-Week Low | $0.30 |
Recent News and Developments
In 2023, Iterum Therapeutics plc announced:
- FDA approval for a new antibiotic candidate.
- Collaboration with major pharmaceutical companies for drug development.
- Plans to expand research facilities in Ireland.
Iterum Therapeutics plc (ITRM) Mission Statement
Company Overview
Iterum Therapeutics plc, a biopharmaceutical company, is focused on developing and commercializing novel antimicrobials to treat infections caused by multi-drug resistant organisms. The mission statement succinctly reflects the company's commitment to addressing these pressing medical needs.
Mission Statement
The mission of Iterum Therapeutics is to develop and commercialize innovative therapeutics that will specifically target multi-drug resistant infections, thereby enhancing patient outcomes and improving the overall quality of care.
Strategic Goals
- To advance the development of cipargamin, a novel antibiotic targeting multi-drug resistant Gram-negative bacterial infections.
- To foster collaborations that enhance research and development efforts.
- To ensure regulatory compliance while providing affordable treatments to healthcare providers and patients.
Financial Overview
As of the latest financial reports, Iterum Therapeutics had a total revenue of approximately $2.6 million for Q2 2023. The company had a cash position of $38.7 million as of June 30, 2023.
Investment and Market Potential
Iterum Therapeutics aims to penetrate the estimated $45 billion global antimicrobial market by addressing the increasing prevalence of drug-resistant infections.
Recent Developments
| Event | Date | Details |
|---|---|---|
| FDA Approval | November 2022 | Received FDA approval for the use of cipargamin for treatment of complicated urinary tract infections. |
| Clinical Trials | March 2023 | Initiated Phase 3 clinical trials for cipargamin. |
Partnerships and Collaborations
- Partnership with University of Minnesota for research on antimicrobial resistance.
- Collaboration with Health Canada for regulatory strategies.
Community Engagement
Iterum Therapeutics invests in community health initiatives, allocating around $1 million annually towards educational programs aimed at antibiotic stewardship.
Future Outlook
The company projects a growth trajectory with a forecast of $50 million in revenue by 2025, driven by new product launches and global market expansion.
Key Performance Indicators
| Indicator | Target | Current Status |
|---|---|---|
| Annual Revenue Growth | 20% | 15% |
| R&D Investment as % of Revenue | 30% | 25% |
| Time to Market | 24 months | 18 months |
Regulatory Strategies
Iterum Therapeutics is actively engaging with the FDA and EMA to ensure compliance and expedite the approval process for its products, with an emphasis on fast track designations for its most promising therapies.
Conclusion
Iterum Therapeutics remains dedicated to its mission of innovating and expanding access to effective antibiotic therapies, addressing a critical area of public health through a robust portfolio and strategic initiatives.
How Iterum Therapeutics plc (ITRM) Works
Company Overview
Iterum Therapeutics plc is a clinical-stage pharmaceutical company focused on developing and commercializing novel anti-infectives to treat multi-drug resistant infections. The company is headquartered in Dublin, Ireland, with a significant presence in the United States. As of the latest financial reports in Q3 2023, Iterum has a market capitalization of approximately $49 million.
Key Products
The company's primary product candidates include:
- Iterum's flagship drug, sulopenem, designed to treat complicated urinary tract infections (cUTIs) and other serious bacterial infections.
- Other investigational drugs targeting various infections resistant to standard antibiotics.
Clinical Development
Iterum Therapeutics employs a robust clinical development strategy with several phases of clinical trials. As of October 2023:
- Phase 3 clinical trial for sulopenem has over 600 patients enrolled in the study.
- The company has accumulated about $20 million in funding for its clinical trials.
Financial Performance
In the most recent earnings report for Q2 2023, Iterum Therapeutics reported the following financial performance metrics:
| Metric | Q2 2023 | Q1 2023 | Q2 2022 |
|---|---|---|---|
| Revenue | $500,000 | $1 million | $750,000 |
| Net Loss | $10.5 million | $9 million | $8 million |
| Research & Development Expenses | $7 million | $6 million | $5 million |
| Cash & Cash Equivalents | $15 million | $25 million | $30 million |
Market Landscape
Iterum operates in the global antibiotic market, which was valued at approximately $49 billion in 2022 and is expected to reach $63 billion by 2027, growing at a CAGR of around 5.3%. The company's focus on antibiotic resistance positions it favorably in a market that is increasingly under pressure from resistant strains.
Collaborations and Partnerships
Iterum has established key partnerships to enhance its research capabilities:
- In 2021, it formed a collaboration with the University of Arizona to utilize its research facilities.
- Partnership with the Global Antibiotic Research & Development Partnership (GARDP) to promote innovative solutions for antibiotic resistance.
Stock Performance
As of October 2023, ITRM trades at approximately $0.45 per share. The stock has shown significant volatility, dropping around 30% over the past three months.
Regulatory Environment
Iterum Therapeutics navigates a complex regulatory environment, focusing on obtaining FDA approval for its lead product, sulopenem, which is currently under review. The company anticipates potential approval by Q2 2024.
Future Outlook
Iterum’s strategic emphasis on developing innovative antibiotics positions it to capitalize on the growing demand for effective treatments against multi-drug resistant pathogens.
How Iterum Therapeutics plc (ITRM) Makes Money
Product Development and Commercialization
Iterum Therapeutics focuses primarily on the development of novel anti-infective therapies. The company’s lead product candidate, Sulopenem, has been developed to treat various infections, particularly those caused by multi-drug resistant organisms.
Revenue Streams
The primary revenue sources for Iterum Therapeutics include:
- Product Sales: Revenue generated from the sale of approved therapies.
- Licensing Agreements: Financial agreements with pharmaceutical companies for the rights to develop and commercialize their products.
- Grants and Funding: Receipt of government and private grants for research and development.
Financial Overview
As of the end of Q2 2023, Iterum Therapeutics reported:
- Total Revenue: $3.5 million
- Net Loss: $10.8 million
- Cash Reserves: Approximately $30 million
Partnerships and Collaborations
Iterum has established various partnerships that enhance their financial inflow. Notable arrangements include:
- License Agreements: Revenue from licensing arrangements is critical. For instance, a deal with a major pharmaceutical company can yield upfront payments of $5 million or more, along with milestone payments contingent on development success.
- Research Collaborations: Collaborations with academic institutions may result in additional funding, often ranging from $1 million to $3 million.
Market Potential and Competitive Landscape
The global market for antibiotics is projected to reach $46 billion by 2026, with an annual growth rate of approximately 6%. Iterum’s focus on drug-resistant infections positions it strategically within this growing market.
Table of Financial Performance (Q2 2023)
| Financial Metric | Amount (in USD) |
|---|---|
| Total Revenue | $3.5 million |
| Net Loss | $10.8 million |
| Cash Reserves | $30 million |
| Market Capitalization | $50 million (as of August 2023) |
| Projected Market Growth | $46 billion by 2026 |
Investment and Future Projections
Investments from venture capital and other financial markets are essential for Iterum's sustainability. The company has successfully raised:
- $20 million in its latest funding round in Q1 2023.
- Projected funding needs for 2024 are estimated at $15 million to advance Sulopenem through clinical trials.
Regulatory Considerations
Iterum Therapeutics must navigate a rigorous regulatory landscape. Successful approval of its lead product could significantly boost revenue through:
- Market Authorization: Potentially yielding sales of up to $100 million in the initial years post-approval.
- Patent Exclusivity: Offering up to 20 years of market protection to recoup research costs.
Iterum Therapeutics plc (ITRM) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support